Attributes 623% Revenue Growth to Innovative Solutions Serving Patients, Life Sciences Manufacturers, Payers, and Providers

AscellaHealth, a global healthcare and specialty pharmacy (SP) solutions company, today announced it ranked 231 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29^th year. AscellaHealth grew 623% during this period.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231108756824/en/

Dea Belazi, president and CEO, credits this achievement to AscellaHealth’s expert navigation of the complex specialty and rare disease ecosystem worldwide and the Company’s growing portfolio of custom solutions for all industry stakeholders.

"With a rare and special perspective, AscellaHealth remains committed to its patient-centric approach built upon proprietary technology processes for programs and services that effectively streamline the commercialization of specialty medications and proactively address unmet client needs,” says Belazi. “Our ongoing success is the result of our position as a trusted, single-source specialty pharmaceutical partner, enhancing clinical outcomes for patients, supporting life sciences manufacturers with tech-enabled, end-to-end solutions from pre-commercialization through market launch and beyond, providing innovative financial services for payers and assisting providers with resources and education for chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies.”

“Each year we look forward to reviewing the progress and innovations of our Technology Fast 500 winners. This year is especially celebratory as we expand the number of winners to better represent just how many companies are developing new ideas to progress our society and the world, especially during a slow economy,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “While software and services and life sciences continue to dominate the top 10, we are encouraged to see other categories making their mark. Congratulations to all the winners who show us how creativity, hard work and perseverance can lead to success.”

“As for growing companies, it’s always rewarding to be recognized for the ongoing commitment it takes to navigate obstacles, transform when necessary and ultimately create a thriving business,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit and assurance practice. “Over the nearly 30 years we’ve been compiling the Technology Fast 500, we’ve seen new categories emerge, growth rates explode, and certain regional markets shine from the bright talent they attract. We are proud of all the winners for achieving this well-deserved honor.”

About the 2023 Deloitte Technology Fast 500

Now in its 29th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About AscellaHealth LLC

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, including Deloitte Technology Fast 500™ and Inc. 5000, AscellaHealth’s customized, patient-centric approach is built upon proprietary technology processes for end-to-end solutions to streamline the commercialization of specialty medications and proactively address unmet client needs, optimize clinical health outcomes and improve the quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit www.AscellaHealth.com.

About Deloitte

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they build their future. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 457,000 people worldwide connect for impact at www.deloitte.com.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108756824/en/